BE1003053A3 - Composition pharmaceutique a base de salmeterol et du propionate de fluticasone. - Google Patents

Composition pharmaceutique a base de salmeterol et du propionate de fluticasone. Download PDF

Info

Publication number
BE1003053A3
BE1003053A3 BE9000862A BE9000862A BE1003053A3 BE 1003053 A3 BE1003053 A3 BE 1003053A3 BE 9000862 A BE9000862 A BE 9000862A BE 9000862 A BE9000862 A BE 9000862A BE 1003053 A3 BE1003053 A3 BE 1003053A3
Authority
BE
Belgium
Prior art keywords
salmeterol
pharmaceutical composition
fluticasone propionate
composition based
treatment
Prior art date
Application number
BE9000862A
Other languages
English (en)
French (fr)
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1003053(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1003053A3 publication Critical patent/BE1003053A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
BE9000862A 1989-09-08 1990-09-07 Composition pharmaceutique a base de salmeterol et du propionate de fluticasone. BE1003053A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
BE1003053A3 true BE1003053A3 (fr) 1991-11-05

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
BE9000862A BE1003053A3 (fr) 1989-09-08 1990-09-07 Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.

Country Status (20)

Country Link
EP (1) EP0416951B1 (2)
JP (1) JP3042867B2 (2)
AT (1) ATE99941T1 (2)
BE (1) BE1003053A3 (2)
CA (1) CA2024916C (2)
CH (1) CH680983C9 (2)
DE (2) DE69005951T2 (2)
DK (1) DK0416951T3 (2)
ES (1) ES2062392T3 (2)
FR (1) FR2651677B1 (2)
HK (1) HK18695A (2)
HU (1) HU211272A9 (2)
IE (1) IE65535B1 (2)
IL (1) IL95590A (2)
IT (1) IT1241996B (2)
LU (1) LU90392I2 (2)
NL (1) NL990012I2 (2)
NZ (1) NZ235221A (2)
PH (1) PH27594A (2)
SG (1) SG166294G (2)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2123909C (en) * 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
IT1317904B1 (it) 1999-09-11 2003-07-15 Glaxo Group Ltd Formulazione farmaceutica di propionato di fluticasone.
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CA2417826A1 (en) * 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
ES2305438T5 (es) † 2002-02-04 2012-06-05 Glaxo Group Limited Formulación para inhalación que comprende un glucocorticoide y un agonista del ?2-adreno-receptor.
JP2005519110A (ja) * 2002-03-04 2005-06-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なケイ皮酸塩、その調製方法及び医薬品としての使用
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
US20070071689A1 (en) 2003-08-06 2007-03-29 Galephar M/F Advantageous combination for inhalation of nacystelyn and bronchodilators
EP1732526A2 (en) * 2004-03-12 2006-12-20 Cipla Ltd. Salmeterol inhalation formulations
EP1616592B9 (en) 2004-07-16 2011-02-02 Almirall, S.A. Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge for use with this inhaler
CN101600469B (zh) 2006-12-22 2013-10-23 奥米罗有限公司 药粉吸入装置
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT2435025T (pt) 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
MX2015015132A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715A (en) * 1981-10-19 1983-05-05 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB2140800A (en) * 1983-04-18 1984-12-05 Glaxo Group Ltd Phenethanolamine derivatives
EP0223671A1 (fr) * 1985-10-16 1987-05-27 Centre International De Recherches Dermatologiques Galderma - Cird Galderma Médicament à action synergétique anti-inflammatoire à base d'un corticostéroide et d'un beta-agoniste

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715A (en) * 1981-10-19 1983-05-05 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB2140800A (en) * 1983-04-18 1984-12-05 Glaxo Group Ltd Phenethanolamine derivatives
EP0223671A1 (fr) * 1985-10-16 1987-05-27 Centre International De Recherches Dermatologiques Galderma - Cird Galderma Médicament à action synergétique anti-inflammatoire à base d'un corticostéroide et d'un beta-agoniste

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UNLISTED DRUGS, vol. 33, no. 6, juin 1981, page 101, Chatham, New Jersey, US *

Also Published As

Publication number Publication date
LU90392I2 (fr) 1999-06-28
CA2024916A1 (en) 1991-03-09
CA2024916C (en) 2002-07-09
SG166294G (en) 1995-06-16
EP0416951A1 (en) 1991-03-13
NL990012I2 (nl) 1999-09-01
CH680983A5 (2) 1992-12-31
IT9048260A0 (it) 1990-09-07
IE65535B1 (en) 1995-11-01
ATE99941T1 (de) 1994-01-15
FR2651677B1 (fr) 1993-08-06
CH680983C1 (2) 2008-06-25
JP3042867B2 (ja) 2000-05-22
IL95590A (en) 1996-06-18
HK18695A (en) 1995-02-17
IE903256A1 (en) 1991-03-13
DK0416951T3 (da) 1994-02-14
DE69005951T2 (de) 1994-05-26
FR2651677A1 (fr) 1991-03-15
IL95590A0 (en) 1991-09-16
NL990012I1 (nl) 1999-07-01
NZ235221A (en) 1992-11-25
DE69005951D1 (de) 1994-02-24
JPH03167120A (ja) 1991-07-19
HU211272A9 (en) 1995-11-28
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
EP0416951B1 (en) 1994-01-12
PH27594A (en) 1993-08-31
CH680983C9 (2) 2008-08-15
DE19975040I2 (de) 2006-07-13
IT1241996B (it) 1994-02-02

Similar Documents

Publication Publication Date Title
FR2651677B1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
KR970704422A (ko) 투여용 약제학적 조성물
AU644094B2 (en) Medicaments
JP2716155B2 (ja) ベーター−２−ミメテイツクスのガレン製剤及びその製造方法
FR2414913A1 (fr) Composition pharmaceutique et dispositif pour l'administration d'antihistaminiques par inhalation
JP2002511385A5 (2)
BE1003093A3 (fr) Procede de preparation d'une composition pharmaceutique sous forme de microparticules.
RU94030722A (ru) Аэрозольная фармацевтическая композиция, лекарственное средство с модифицированной поверхностью, баллон для доставки фармацевтической композиции, ингалятор, способ лечения респираторных заболеваний
IS4516A (is) Nýtt lyfjaform
FR2622798B1 (fr) Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
ATE196081T1 (de) L-dopa ester enthaltende zusammensetzung
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
CA2034519A1 (en) Pharmaceutical compositions and dosage forms for the oral administration of calcitonin
MA27062A1 (fr) Compositions pour inhalation, comprenant des 5, 6-dihydro-9h-pyrazolo [3, 4-c]-1, 2, 4-triazolo [4, 3- ] pyridines tricycliques
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
MY111155A (en) Medicaments
JPS6360926A (ja) 感冒薬
JPS62181215A (ja) 肺線維症改善剤およびその使用

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: S.A. *GLAXOSMITHKLINE

Effective date: 20100907

CCRE Expiry of a supplementary protection certificate

Owner name: *GLAXO GROUP LTD

Free format text: PRODUCT NAME: SALMETEROL XINAFOAS / FLUTICASON. PROPIONAS; NATL. REGISTRATION NO/DATE: 725 IS 361 F11 19990322; FIRST REGISTRATION: SE 14591 19980907

Spc suppl protection certif: 99C0020

Filing date: 19990512

Expiry date: 20100907

Extension date: 20130907

Effective date: 20130907